United States· US:72511-393_d9a0c476-16cf-46ae-8525-a89da9d76fc4
REPATHA
A evolocumab product containing evolocumab, registered in United States by Amgen USA Inc.. The same ATC class is registered in 15 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Evolocumab is registered in 15 of 19 countries.
Countries holding a registration under ATC C10AX13 (evolocumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 10 of them publish a price we can compare per daily dose
Evolocumab · ATC C10AX13
15 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of evolocumab costs, country by country.
Normalised to the WHO defined daily dose (10 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Evolocumab · price per daily dose (10 mg)
USD · FX 28 Sept 2026
- CH Switzerland$17.24
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- EVOLOCUMAB
- Manufacturer
- Amgen USA Inc.
- Country
- United States (US)
- ATC code
- C10AX13
- ATC class
- Evolocumab
- Defined daily dose
- 10 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- July 26, 2026
Packs & prices · 6
- ndc1172511-393-01
- ndc1172511-393-02
- ndc1172511-393-96
- ndc1172511393011 SYRINGE in 1 CARTON (72511-393-01) / 1 mL in 1 SYRINGE
- ndc1172511393022 SYRINGE in 1 CARTON (72511-393-02) / 1 mL in 1 SYRINGE
- ndc1172511393961 SYRINGE in 1 CARTON (72511-393-96) / 1 mL in 1 SYRINGE
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Evolocumab in 16 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaREPATHAAmgen Europe B.V., Breda
- FinlandRepathaAmgen Europe B.V.
- IrelandRepatha 140 mg solution for injection in pre-filled penAmgen Europe B.V.
- SpainREPATHA 140 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAAmgen Europe B.V.
- IcelandRepathaAmgen Europe B.V.*
- NetherlandsRepatha 140 mg oplossing voor injectie in een voorgevulde penAmgen Europe B.V.
- SwedenRepatha 140 mg Injektionsvätska, lösning i förfylld injektionspennaAmgen Europe B.V.
- United KingdomRepatha 140mg/1ml solution for injection pre-filled syringesAmgen Ltd
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Repatha
- Norway · Repatha
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/55ff0de4-a925-47d9-a952-442a0d12b187 GET /v1/drugs/55ff0de4-a925-47d9-a952-442a0d12b187?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "140",
"substance": "EVOLOCUMAB",
"productndc": "72511-393",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125522",
"marketing_category": "BLA"
}See everything about evolocumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.